Myasthenia Gravis Treatment Global Market Report 2025

Description

Myasthenia gravis treatment encompasses the provision of healthcare services by healthcare providers to address and manage myasthenia gravis, an autoimmune neuromuscular disease characterized by fatigue and weakness in the skeletal muscles.

The primary modalities for treating myasthenia gravis include medication, surgery, and other interventions. Medication involves the use of drugs to alleviate the symptoms associated with myasthenia gravis. One commonly prescribed medication is pyridostigmine, which facilitates the transmission of electrical signals between nerves and muscles. The treatment approach for myasthenia gravis incorporates various types of medications, such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others. These medications are administered in healthcare settings, including hospitals, clinics, and other healthcare facilities, to effectively manage the condition and improve the quality of life for patients.

The myasthenia gravis treatment market research report is one of a series of new reports from The Business Research Company that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the emergence of plasma exchange, and patient advocacy

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, and long-term safety monitoring.

The rise in the incidence of myasthenia gravis is anticipated to drive the growth of the myasthenia gravis treatment market in the future. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fatigue and weakness in the skeletal muscles. Treatment for myasthenia gravis involves delivering healthcare services and care to help patients manage the condition. Consequently, the increasing prevalence of myasthenia gravis is enhancing sales in the treatment market. For instance, data published by the National Organization for Rare Disorders in January 2022 indicated that autoimmune myasthenia gravis has an estimated prevalence of 14-40 per 100,000 individuals in the United States. Additionally, a report from the American Journal of Managed Care in April 2024, based on an average of 1,800 annual diagnoses, estimated an incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Thus, the growing prevalence of myasthenia gravis is fueling the expansion of the myasthenia gravis treatment market.

Rising healthcare spending is fueling growth in the myasthenia gravis treatment market. Healthcare spending represents the total financial resources allocated to the healthcare sector within a given region, country, or organization. Such spending is essential for treating myasthenia gravis (MG), an autoimmune neuromuscular disorder, as it supports optimal patient care, symptom management, and enhanced quality of life. For example, in July 2024, the American Medical Association, a U.S.-based professional association and lobbying group of physicians and medical students, reported that health spending in the United States rose by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per capita. Therefore, increased healthcare spending is propelling the growth of the myasthenia gravis treatment market.

Product innovations are becoming a significant trend in the myasthenia gravis treatment market. Key companies in this sector are concentrating on developing new solutions to maintain their competitive edge. For example, in October 2023, UCB Pharma, a pharmaceutical company based in Belgium, announced that the US Food and Drug Administration (FDA) approved Zilucoplan for treating adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval adds a new treatment option for managing gMG, which is characterized by muscle weakness stemming from an autoimmune response. ZILBRYSQ stands out as a self-administered, once-daily subcutaneous complement C5 inhibitor, offering a convenient alternative to the traditional intravenous therapies that have long been the standard for treating gMG.

Major players in the myasthenia gravis treatment market are strategically embracing partnerships to usher in a patient-centric approach and redefine the delivery of care to rare disease populations. Strategic partnerships, characterized by the mutual leveraging of strengths and resources, have become a key avenue for collaboration. An illustrative example is the partnership between Huma Therapeutics, a UK-based digital health company, and UCB S.A., a Belgium-based biopharmaceutical company, announced in April 2023. This collaboration aims to introduce a digital health solution to enhance the management of the rare disease Myasthenia gravis (MG).

In November 2023, Selecta Biosciences, Inc., a biotechnology company based in the United States, announced its merger with Cartesian Therapeutics for an undisclosed amount. This merger enhances Selecta's dedication to RNA cell therapies for autoimmune diseases, particularly myasthenia gravis (MG). The partnership aims to leverage Cartesian's advanced RNA-engineering platform and pipeline, which includes the promising rCAR-T therapy Descartes-08, to accelerate development and provide effective treatment options. Cartesian Therapeutics is also a US-based biotechnology company focused on developing potential treatments for generalized myasthenia gravis.

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myasthenia Gravis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myasthenia gravis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myasthenia gravis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myasthenia gravis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment: Medication; Surgery; Other Treatments
2) By Medication Type: Cholinesterase Inhibitors; Corticosteroids; Immunosuppressants; Other Medication Types
3) By End-Use: Hospitals; Clinics; Other End-Uses
Subsegments:
1) By Medication: Anticholinesterase Agents; Immunosuppressants; Monoclonal Antibodies; Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis; Intravenous Immunoglobulin (IVIg); Supportive Therapies
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25130

1. Executive Summary

2. Myasthenia Gravis Treatment Market Characteristics

3. Myasthenia Gravis Treatment Market Trends And Strategies

4. Myasthenia Gravis Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Myasthenia Gravis Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Myasthenia Gravis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Myasthenia Gravis Treatment Market Growth Rate Analysis
5.4. Global Myasthenia Gravis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Myasthenia Gravis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Myasthenia Gravis Treatment Total Addressable Market (TAM)

6. Myasthenia Gravis Treatment Market Segmentation

6.1. Global Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medication
Surgery
Other Treatments
6.2. Global Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cholinesterase Inhibitors
Corticosteroids
Immunosuppressants
Other Medication Types
6.3. Global Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End-Uses
6.4. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anticholinesterase Agents
Immunosuppressants
Monoclonal Antibodies
Corticosteroids
6.5. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Thymectomy
6.6. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasmapheresis
Intravenous Immunoglobulin (IVIg)
Supportive Therapies

7. Myasthenia Gravis Treatment Market Regional And Country Analysis

7.1. Global Myasthenia Gravis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Myasthenia Gravis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myasthenia Gravis Treatment Market

8.1. Asia-Pacific Myasthenia Gravis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myasthenia Gravis Treatment Market

9.1. China Myasthenia Gravis Treatment Market Overview
9.2. China Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myasthenia Gravis Treatment Market

10.1. India Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myasthenia Gravis Treatment Market

11.1. Japan Myasthenia Gravis Treatment Market Overview
11.2. Japan Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myasthenia Gravis Treatment Market

12.1. Australia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myasthenia Gravis Treatment Market

13.1. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myasthenia Gravis Treatment Market

14.1. South Korea Myasthenia Gravis Treatment Market Overview
14.2. South Korea Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myasthenia Gravis Treatment Market

15.1. Western Europe Myasthenia Gravis Treatment Market Overview
15.2. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myasthenia Gravis Treatment Market

16.1. UK Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myasthenia Gravis Treatment Market

17.1. Germany Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myasthenia Gravis Treatment Market

18.1. France Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myasthenia Gravis Treatment Market

19.1. Italy Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myasthenia Gravis Treatment Market

20.1. Spain Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myasthenia Gravis Treatment Market

21.1. Eastern Europe Myasthenia Gravis Treatment Market Overview
21.2. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myasthenia Gravis Treatment Market

22.1. Russia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myasthenia Gravis Treatment Market

23.1. North America Myasthenia Gravis Treatment Market Overview
23.2. North America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myasthenia Gravis Treatment Market

24.1. USA Myasthenia Gravis Treatment Market Overview
24.2. USA Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myasthenia Gravis Treatment Market

25.1. Canada Myasthenia Gravis Treatment Market Overview
25.2. Canada Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myasthenia Gravis Treatment Market

26.1. South America Myasthenia Gravis Treatment Market Overview
26.2. South America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myasthenia Gravis Treatment Market

27.1. Brazil Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myasthenia Gravis Treatment Market

28.1. Middle East Myasthenia Gravis Treatment Market Overview
28.2. Middle East Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myasthenia Gravis Treatment Market

29.1. Africa Myasthenia Gravis Treatment Market Overview
29.2. Africa Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myasthenia Gravis Treatment Market Competitive Landscape And Company Profiles

30.1. Myasthenia Gravis Treatment Market Competitive Landscape
30.2. Myasthenia Gravis Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Myasthenia Gravis Treatment Market Other Major And Innovative Companies

31.1. Takeda Pharmaceutical Company Limited
31.2. Baxter International Inc.
31.3. Biogen Idec
31.4. Astellas Pharma Inc.
31.5. CSL Limited
31.6. Chugai Pharmaceutical Co. Ltd.
31.7. Grifols S.A
31.8. UCB Inc.
31.9. Mitsubishi Tanabe Pharma Corp.
31.10. Genentech Inc.
31.11. Horizon Therapeutics plc
31.12. Amneal Pharmaceuticals Inc.
31.13. Kedrion SpA
31.14. CuraVac Inc.
31.15. AryoGen Pharmed

32. Global Myasthenia Gravis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market

34. Recent Developments In The Myasthenia Gravis Treatment Market

35. Myasthenia Gravis Treatment Market High Potential Countries, Segments and Strategies

35.1 Myasthenia Gravis Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Myasthenia Gravis Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Myasthenia Gravis Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer